Genelux shared a post on LinkedIn:
“We are pleased to announce the appointment of Jason Litten as Chief Medical Officer at Genelux Corporation.
Dr. Litten brings over 20 years of experience in oncology drug development, with a proven track record of advancing innovative therapies from early-stage research through late-stage trials. His leadership will be instrumental as we progress Olvi-Vec through pivotal milestones and continue our mission to deliver next-generation hashtag#immunotherapies for patients facing aggressive hashtag#cancers.
Welcome to the team, Dr. Litten!
Read the full press release.”
More posts on OncoDaily.